ATE543512T1 - Verwendung von impfstoffen zur behandlung/prävention der übertragung von influenza-erregern zwischen spezies - Google Patents

Verwendung von impfstoffen zur behandlung/prävention der übertragung von influenza-erregern zwischen spezies

Info

Publication number
ATE543512T1
ATE543512T1 AT06836580T AT06836580T ATE543512T1 AT E543512 T1 ATE543512 T1 AT E543512T1 AT 06836580 T AT06836580 T AT 06836580T AT 06836580 T AT06836580 T AT 06836580T AT E543512 T1 ATE543512 T1 AT E543512T1
Authority
AT
Austria
Prior art keywords
vaccines
treat
prevent inter
species transmission
influenza
Prior art date
Application number
AT06836580T
Other languages
English (en)
Inventor
Juergen Daemmgen
Eric Vaughn
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Application granted granted Critical
Publication of ATE543512T1 publication Critical patent/ATE543512T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT06836580T 2005-10-28 2006-10-27 Verwendung von impfstoffen zur behandlung/prävention der übertragung von influenza-erregern zwischen spezies ATE543512T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73099805P 2005-10-28 2005-10-28
PCT/US2006/041989 WO2007053446A2 (en) 2005-10-28 2006-10-27 Use of vaccines for the treatment/ prevention of the transmission of influenza pathogens between species

Publications (1)

Publication Number Publication Date
ATE543512T1 true ATE543512T1 (de) 2012-02-15

Family

ID=38006396

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06836580T ATE543512T1 (de) 2005-10-28 2006-10-27 Verwendung von impfstoffen zur behandlung/prävention der übertragung von influenza-erregern zwischen spezies

Country Status (12)

Country Link
US (1) US8883123B2 (de)
EP (1) EP1942924B1 (de)
JP (1) JP2009513667A (de)
KR (1) KR20080065680A (de)
CN (2) CN102406932A (de)
AR (1) AR056733A1 (de)
AT (1) ATE543512T1 (de)
AU (1) AU2006309007A1 (de)
BR (1) BRPI0617952A2 (de)
CA (1) CA2626866A1 (de)
TW (1) TW200731986A (de)
WO (1) WO2007053446A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0617952A2 (pt) 2005-10-28 2011-08-09 Boehringer Ingelheim Vetmed composição antigênica compreendendo um antìgeno de um patógeno de um animal de uma primeira espécie, bem como uso de vacinas para o tratamento/prevenção da transmissão de patógenos da gripe entre espécies
US8202967B2 (en) * 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
US20090246226A1 (en) * 2008-03-28 2009-10-01 Zeon Corporation Avian vaccines possessing a positive marker gene
DE102008002641A1 (de) * 2008-06-25 2009-12-31 Biotronik Vi Patent Ag Faserstrang und implantierbarer Stützkörper mit einem Faserstrang
WO2010021289A1 (ja) * 2008-08-18 2010-02-25 学校法人北里研究所 トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを併用したトリインフルエンザワクチンの追加免疫方法
AU2008364200B2 (en) * 2008-11-19 2016-01-28 Laboratorio Avi-Mex, S.A. De C.V. Recombinant inactivated viral vector vaccine
MX2011005604A (es) 2008-11-28 2011-09-01 Merial Ltd Vacuna recombinante para influenza aviar y sus usos.
AR088028A1 (es) * 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
EP2958586B1 (de) * 2013-02-21 2018-09-05 Boehringer Ingelheim Vetmedica GmbH H5-proteine aus dem h5n1-influenzavirus zur verwendung als arzneimittel
WO2015028478A1 (en) 2013-08-28 2015-03-05 Glaxosmithkline Biologicals S.A. Novel influenza antigens and antibodies
US12098166B2 (en) * 2018-11-06 2024-09-24 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition against avian influenza virus H5 subtype
MX2023012554A (es) 2018-12-12 2023-11-08 Cambridge Tech Llc Vacuna universal contra la gripe.
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
AU2021252164B2 (en) 2020-04-09 2026-07-02 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552758A (en) * 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
WO2002062381A1 (en) 2001-02-05 2002-08-15 Hisamitsu Pharmaceutical Co., Inc. Baculovirus vector vaccine
EP1413315A4 (de) 2001-08-03 2006-08-16 Takeda Pharmaceutical Medikamente mit verzögerter freisetzung
EP1633312A4 (de) 2003-06-16 2012-09-26 Medimmune Llc Influenza-hämagglutinin- und neuraminidase-varianten
US20080254065A1 (en) * 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
CN1748795A (zh) 2004-09-17 2006-03-22 金宁一 多价禽流感重组活载体疫苗
KR20060089393A (ko) * 2005-02-04 2006-08-09 주식회사 중앙백신연구소 돼지 인플루엔자 바이러스ａ／ｓｗｉｎｅ／ｋｏｒｅａ／ｓ83/2004(ｈ9ｎ2) 및 이의백신
KR20080052509A (ko) 2005-04-11 2008-06-11 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 유행성 독감 바이러스에 대한 백신
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
BRPI0617952A2 (pt) 2005-10-28 2011-08-09 Boehringer Ingelheim Vetmed composição antigênica compreendendo um antìgeno de um patógeno de um animal de uma primeira espécie, bem como uso de vacinas para o tratamento/prevenção da transmissão de patógenos da gripe entre espécies
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use

Also Published As

Publication number Publication date
JP2009513667A (ja) 2009-04-02
BRPI0617952A2 (pt) 2011-08-09
US20070207168A1 (en) 2007-09-06
EP1942924A2 (de) 2008-07-16
WO2007053446A3 (en) 2007-08-16
CA2626866A1 (en) 2007-05-10
KR20080065680A (ko) 2008-07-14
WO2007053446A2 (en) 2007-05-10
US8883123B2 (en) 2014-11-11
AU2006309007A8 (en) 2008-06-19
EP1942924B1 (de) 2012-02-01
CN102406932A (zh) 2012-04-11
AU2006309007A1 (en) 2007-05-10
AR056733A1 (es) 2007-10-17
TW200731986A (en) 2007-09-01
CN101300023A (zh) 2008-11-05

Similar Documents

Publication Publication Date Title
EP2278999C0 (de) Ohrbehandlungsformulierungen zur behandlung von ohrenerkrankungen und -leiden
EP2182983A4 (de) Behandlung von amyloidogenen erkrankungen
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
ATE545418T1 (de) Zusammensetzungen und kits zur behandlung von influenza
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP3871639C0 (de) Vorrichtung zur behandlung von gastroösophagealer refluxkrankheit
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
EP2249861A4 (de) Behandlung von neurodegenerativen erkrankungen mit progranulin (pgrn)
EP3861968C0 (de) Vorrichtungen zur behandlung von schlafapnoe
DE202012013074U8 (de) Zusammensetzungen zur Behandlung von HCV
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
EP2421364A4 (de) Verwendung von guanethidin zur behandlung von bluthochdruck über lokale vaskuläre freisetzung
EP2175873A4 (de) Behandlung von angstzuständen
EP2579936A4 (de) Magensonde zur behandlung von adipositas
ATE532507T1 (de) Neramexane zur behandlung von subakuten tinnitus
EP2470553C0 (de) Polyhydroylierte gallensäure zur behandlung von gallenerkrankungen
ATE533774T1 (de) Neuartige nukleosidanaloge zur behandlung von virusinfektionen
DK2236149T3 (da) Medicinsk sammensætning til behandling af respiratoriske infektions-sygdomme
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
DE602007008494D1 (de) Verwendung von Agomelatin zur Herstellung von Medikamenten zur Behandlung der generalisierten Angststörung
EP3769718C0 (de) Vorrichtung zur behandlung von darmerkrankungen
EP2247297A4 (de) Therapeutische behandlung von lungenerkrankungen
EP2249765A4 (de) Dapson zur behandlung von rosascea
EP2411004A4 (de) Verwendung von andrographolidverbindungen zur behandlung von entzündungen und atemwegserkrankungen